What is Lincoln Diagnostics?
Lincoln Diagnostics operates as a critical infrastructure provider within the medical diagnostics sector, specializing in disposable allergy skin testing technology. By delivering high-utility products such as the UniTest PC and Multi-Test PC, the company addresses the essential needs of teaching hospitals, private clinics, and large-scale medical institutions. Their adherence to stringent OSHA compliance standards, combined with a presence across five continents, positions them as a reliable partner in the global allergy testing ecosystem. The company's focus on affordability and clinical precision has allowed it to maintain a competitive edge in a highly regulated industry, ensuring that healthcare providers have consistent access to diagnostic tools that improve patient outcomes.
How much funding has Lincoln Diagnostics raised?
Lincoln Diagnostics has raised a total of $720K across 2 funding rounds:
Debt
$350K
Debt
$370K
Debt (2020): $350K with participation from PPP
Debt (2021): $370K led by PPP
Key Investors in Lincoln Diagnostics
PPP
Public-Private Partnership
What's next for Lincoln Diagnostics?
With the recent capital deployment, Lincoln Diagnostics is well-positioned to accelerate its international expansion and further optimize its supply chain logistics. The company's strategic focus will likely shift toward deepening its penetration in emerging markets while continuing to innovate its core product line to meet evolving clinical requirements. By leveraging its established global distribution footprint, Lincoln Diagnostics aims to capitalize on the increasing demand for standardized allergy testing protocols. Future growth will be driven by the integration of advanced manufacturing efficiencies and the expansion of its institutional client base, ensuring that the firm remains at the forefront of diagnostic innovation and operational excellence in the medical device sector.
See full Lincoln Diagnostics company page
